News and Research

Prescient Therapeutics obtains two key licences to develop ‘chimeric immune receptor platform’ OmniCAR

Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant licences related to its universal ...
Read More
| News

Prescient Therapeutics obtains two key licences to develop ‘chimeric immune receptor platform’ OmniCAR

Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant licences related to its universal ...
Read More
| News

Prescient Therapeutics (ASX:PTX) locks in two licences for new cell therapy tech

Anti-cancer biotech company Prescient Therapeutics (PTX) has received two key licences to build a new cell therapy platform. Prescient revealed ...
Read More
| News

Successful treatments for cancer have never been more important

It is impossible to overstate the unprecedented disruptions the world is facing with COVID-19. Stock markets have plunged worldwide and ...
Read More
| News

CAR-T cancer therapy is a win for immunocompromised kids like Grace

AFL player Ben Brown recently shared a story about his cousin Grace’s battle with cancer, imploring people to stay home ...
Read More
| News

Receive Email Updates

To stay fully updated on Prescient Therapeutics Corporate Activity and Company Announcements, please subscribe for up to the minute updates

WEBCAST AND MEDIA

PTX Investor Briefing - 28 January

PTX Live Investor Briefing – 26 November

PTX CEO Steven Yatomi Clarke discusses Prescient Therapeutics treatments in detail

Follow us and stay connected